ArticleJournal of diabetes2025
Dickkopf1 as a Potential Biomarker in Polycystic Ovary Syndrome and Insulin Resistance: A Cross-Sectional Study.
Article in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dickkopf1 as a Potential Biomarker in Polycystic Ovary Syndrome and Insulin Resistance: A Cross-Sectional Study.Journal of diabetes · 2025Article
- A Cross-Sectional Exploratory Study of Cardiovascular Risk Biomarkers in Non-Obese Women with and without Polycystic Ovary Syndrome: Association with Vitamin D.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDickkopf1 (DKK1) is a protein with established links to metabolic diseases. However, its association with polycystic ovary syndrome (PCOS) and insulin resistance (IR) remains ambiguous.
methodsWe conducted a cross-sectional study involving 300 participants, including 100 healthy women, 100 women with PCOS, and 100 individuals with IR. Protein interactions with DKK1 were identified using the STRING database, followed by KEGG and GO analyses to explore enriched biological processes. Serum DKK1 and Adipoq levels were measured using ELISA kits. The hepatic DKK1 was detected by western blotting.
resultsBoth IR and PCOS groups showed significantly higher serum DKK1 levels and lower Adipoq levels compared to controls. Serum DKK1 levels positively correlated with body mass index (BMI), waist-hip ratio (WHR), body fat percentage (FAT%), systolic blood pressure (SBP), triglycerides (TG), fasting plasma glucose (FPG), fasting insulin (FIns), glycosylated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR). Adipoq levels negatively correlated with glucose disposal rate (M-value). Multiple regression analysis showed that BMI and Adipoq were independent factors affecting DKK1. Multiple stepwise regressions indicated that DKK1 is a risk factor for IR and PCOS. In the euglycemic-hyperinsulinemic clamp (EHC) test, serum DKK1 levels increased in the PCOS patients and decreased in the IR patients at 30 min and returned to baseline at 60 min.
conclusionsElevated DKK1 levels are strongly associated with PCOS and IR, suggesting a potential role in their development. This insight paves the way for further investigations into the role of DKK1 in PCOS and IR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.